- Home
- IPHA vs NKSH Comparison
IPHA vs NKSH Comparison
Compare IPHA & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- NKSH
- Stock Information
- Founded
- IPHA 1999
- NKSH 1891
- Country
- IPHA France
- NKSH United States
- Employees
- IPHA N/A
- NKSH N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- NKSH Major Banks
- Sector
- IPHA Health Care
- NKSH Finance
- Exchange
- IPHA Nasdaq
- NKSH Nasdaq
- Market Cap
- IPHA 160.1M
- NKSH 185.2M
- IPO Year
- IPHA 2019
- NKSH N/A
- Fundamental
- Price
- IPHA $1.82
- NKSH $28.92
- Analyst Decision
- IPHA Strong Buy
- NKSH Strong Buy
- Analyst Count
- IPHA 3
- NKSH 1
- Target Price
- IPHA $5.00
- NKSH $38.00
- AVG Volume (30 Days)
- IPHA 572.8K
- NKSH 10.5K
- Earning Date
- IPHA 09-17-2025
- NKSH 10-23-2025
- Dividend Yield
- IPHA N/A
- NKSH 5.24%
- EPS Growth
- IPHA N/A
- NKSH 41.35
- EPS
- IPHA N/A
- NKSH 2.04
- Revenue
- IPHA $14,839,695.00
- NKSH $51,980,000.00
- Revenue This Year
- IPHA $22.29
- NKSH $2.95
- Revenue Next Year
- IPHA $43.84
- NKSH $9.97
- P/E Ratio
- IPHA N/A
- NKSH $14.10
- Revenue Growth
- IPHA N/A
- NKSH 19.63
- 52 Week Low
- IPHA $1.41
- NKSH $23.75
- 52 Week High
- IPHA $3.51
- NKSH $32.36
- Technical
- Relative Strength Index (RSI)
- IPHA 42.84
- NKSH 47.17
- Support Level
- IPHA $1.73
- NKSH $28.35
- Resistance Level
- IPHA $1.86
- NKSH $30.35
- Average True Range (ATR)
- IPHA 0.12
- NKSH 0.64
- MACD
- IPHA -0.02
- NKSH -0.03
- Stochastic Oscillator
- IPHA 11.51
- NKSH 49.43
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.